Globulol is a sesquiterpene alcohol associated especially with eucalyptus, tea tree, and kunzea-type oils in the AromaForge archive. The evidence base is mixed but usable: identity and repeated oil occurrence are straightforward, an older isolated-compound paper reports antimicrobial effects against several plant-pathogenic fungi, and a very recent preclinical cancer-immunology paper suggests PD-L1-related activity in hepatocellular carcinoma models. That makes globulol more than just a marker constituent, but its standalone literature is still narrow and preclinical, with limited dedicated safety documentation verified in this pass.
Chemical identity and composition
PubChem identifies globulol as C15H26O with InChIKey AYXPYQRXGNDJFU-QTPLKFIXSA-N. NIST records CAS 489-41-8 and lists the species with the same structure under globulol, while also surfacing stereochemical naming variants including ledol. In the local archive, globulol is a recurring oxygenated sesquiterpene in eucalyptus, tea tree, and kunzea records rather than a trace one-off.
Aroma and practical use
- Use the recorded woody, camphoraceous, eucalyptus-like, dry descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
An isolated-compound study from Eucalyptus globulus fruits reported globulol activity against several plant-pathogenic fungi, with the abstract snippet specifically noting IC50 values in mycelial-growth assays.
This is direct evidence on globulol itself rather than a whole-oil mixture, but it is a narrow antimicrobial model rather than a human-health study.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 PubMed-indexed report concluded that globulol could create a microenvironment more permissive to PD-1 blockade and thereby exert anti-hepatocellular-carcinoma activity.
The accessible abstract summary frames the effect as combination-supportive rather than as established standalone oncology evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 Eucalyptus globulus GC-MS and bioactivity paper quantified globulol at 5.9% in crude oil and 26.24% in one fraction, reinforcing its status as a meaningful eucalyptus constituent rather than only a trace analyte.
This supports archive positioning and source context more than a direct isolated-compound mechanism claim.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No verified standalone IFRA limit, dedicated RIFM safety assessment, or human dermal-safety review for isolated globulol was identified in this research pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the preclinical literature is limited and heterogenous, archive language should keep globulol positioned as a constituent with emerging lab evidence rather than established therapeutic or topical-safety outcomes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
antifungal growth inhibition
The 2008 isolated-compound paper supports direct antimicrobial action against several plant-pathogenic fungi, but the abstract-level evidence does not establish a specific molecular target.
This experimental finding does not establish benefit, dose or safety in people using this blend.
PD-L1 reduction in hepatocellular carcinoma models
A 2025 preclinical paper reported that globulol enhanced anti-PD-1 effects by reducing PD-L1 expression, implying an immunomodulatory tumor-microenvironment mechanism in HCC models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No human clinical evidence for isolated globulol was verified.
- Safety coverage for isolated globulol is sparse compared with occurrence data in essential oils.
- The recent immuno-oncology paper is promising but too new and too preclinical to justify broad claims.
- 2026-07-13 verification pass: web search for IFRA/RIFM dermal limit and sensitization data found no authoritative constituent-specific results for globulol; prior dermal_limit_pct (20) and sensitizing (true) were unsourced placeholders and have been corrected to null.
- 2026-07-13 second-pass verification: fetched The Good Scents Company listing for (-)-globulol (CAS 489-41-8) directly. Its Safety Information section lists Oral/Parenteral, Dermal, and Inhalation Toxicity all as 'Not determined' and GHS classification as 'None found,' and its Safety in Use Information section states usage levels are 'not for fragrance use' and 'not for flavor use.' This corroborates (does not overturn) the existing null/false defaults - no numeric dermal limit or sensitization determination exists in this source either, so dermal_limit_pct, sensitizing, and penetration_enhancer remain unverified.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.